Skip to search formSkip to main contentSkip to account menu

tegobuvir

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

GS-9190

Broader (2)

PurinesPyridazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir‐containing regimens without sofosbuvir
The study aimed to evaluate the effects of baseline hepatitis C virus (HCV) nonstructural protein 5A (NS5A) resistance‐associated… 
2015
2015
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.
2013
2013
Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.
2012
2012
The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients… 
2012
2012
Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.
2012
2012
Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3
1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3 Authors: Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam… 
Highly Cited
2011
Highly Cited
2011
Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
ABSTRACT GS-9190 (Tegobuvir) is a novel imidazopyridine inhibitor of hepatitis C virus (HCV) RNA replication in vitro and has… 
2011
2011
445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION
2011
2011
425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS
2011
2011
1211 EMERGENCE AND PERSISTENCE OF NS5B MUTATIONS FOLLOWING COMBINATION TREATMENT WITH TEGOBUVIR (GS-9190) PLUS STANDARD OF CARE-LONG-TERM FOLLOW-UP FROM THE PHASE IIB STUDY GS-US-196-0103
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)